When infection with hepatitis C virus goes from acute to chronic, severe liver disease may occur which requires organ transplantation. Nearly 200 million people are chronically infected with HCV, necessitating approaches to preventing and treating infections. No HCV vaccine is available, and current antiviral therapy consists of administration of interferon plus ribavirin, a combination that …
Hosts: Vincent Racaniello and Michael Gale On episode 85 of the podcast This Week in Virology, Vincent and Michael Gale discuss the origin, pathogenesis, prevention, of hepatitis C virus, and how it evades innate immune responses. This episode is sponsored by Data Robotics Inc. Use the promotion code TWIVPOD to receive $75-$500 off a Drobo. …
TWiV 85: Hepatitis C virus with Professor Michael Gale Read More »
I joined Marc Pelletier on episode 60 of Futures in Biotech for a conversation with Dave Brodbeck, George Farr, and Andre Nantel. We talked about primate face recognition, discovery of a new antiviral compound to treat hepatitis C virus infection, changing the length of a codon from three to four bases, and the sequence of …
Futures in Biotech 60: Do you come to this cave often? Read More »
No, not yet. But the recent identification of human occludin as a cell protein required for entry of hepatitis C virus into mouse cells is a huge step in the right direction. Small animal models for virus infection are of great value for studying viral pathogenesis, testing new vaccines, and developing antiviral drugs. However, mice …
